2003
Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management
Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management. Clinical Lung Cancer 2003, 4: 366-369. PMID: 14599302, DOI: 10.3816/clc.2003.n.016.Peer-Reviewed Original ResearchDermatologic effectsGefitinib treatmentClinical trialsDry skinSide effectsFrequent drug-related adverse effectsDrug-related allergic reactionsRecent phase II trialDrug-related adverse effectsAdverse effectsDermatologic adverse effectsPhase II trialDermatologic side effectsCell lung cancerNumerous clinical trialsSimilar side effectsVariety of treatmentsMechanism of actionAcneiform rashTopical clindamycinAdvanced NSCLCEpidermal growth factor receptor tyrosine kinaseII trialMost patientsGefitinib therapy
2001
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck
Tseng J, Glisson B, Khuri F, Shin D, Myers J, El‐Naggar A, Roach J, Ginsberg L, Thall P, Wang X, Teddy S, Lawhorn K, Zentgraf R, Steinhaus G, Pluda J, Abbruzzese J, Hong W, Herbst R. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 2001, 92: 2364-2373. PMID: 11745292, DOI: 10.1002/1097-0142(20011101)92:9<2364::aid-cncr1584>3.0.co;2-p.Peer-Reviewed Original ResearchConceptsMetastatic squamous cell carcinomaSquamous cell carcinomaPhase II studyCell carcinomaProgressive diseaseII studySurvival timeAntiangiogenic effectsAdvanced squamous cell carcinomaBasic fibroblast growth factor levelsMedian overall survival timeFibroblast growth factor levelsSingle-agent thalidomideSingle-agent antitumor activityEarly-stage diseasePopulation of patientsOverall survival timeGrowth factor levelsVascular endothelial growth factorMinimal residual diseaseSignificant antitumor effectEndothelial growth factorMechanism of actionStage diseaseUnacceptable toxicity